NEW YORK (Reuters Health)—Various image analysis techniques show sex-specific patterns of bone deterioration at the hip, suggesting that men and women should be assessed differently for hip fracture risk, researchers say. “One major contribution of this work is the integration of data-driven computational anatomy approaches, which showed that proximal femur fragility linked to fracture seems…
Articles by Natasha Yetman
Fed Up with Rising Costs, Big U.S. Firms Dig Into Healthcare
SAN JOSE, Calif., (Reuters)—At its Silicon Valley headquarters, network gear maker Cisco Systems Inc. is going to unusual lengths to take control of the relentless increase in its U.S. healthcare costs. The company is among a handful of large American employers who are getting more deeply involved in managing their workers’ health instead of looking…
AbbVie’s RA Drug Succeeds in Late Stage Study
(Reuters)—Abbvie Inc. says its experimental drug met the main goal of halting progression of moderate to severe rheumatoid arthritis (RA) in a late-stage trial. The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate. Upadacitinib, which belongs to a class of drugs known as JAK inhibitors,…
Research Shows High Adherence to Performance Measures for RA Cohort
New research examines the adherence rates for system-level performance measures in Canada. Using data from the Canadian Early Arthritis Cohort that spanned eight years, researchers determined the percentage of RA patients seen in yearly follow-up with the number of gaps between visits, the percentage of RA patients treated with a disease-modifying anti-rheumatic drug and number days from diagnosis to the initiation of treatment. The results: High adherence to system-level performance measures was found in this early RA cohort, with small declines in performance with the increasing length overtime…
Current Graduate Medical Education Can’t Meet Future Needs
In 2005, an ACR Workforce Study estimated the adult rheumatology workforce to be 4,946 providers and projected growth of only 1.2% by 2025, resulting in a projected deficit of 2,576 rheumatologists considering the estimated need. According to the 2015 Workforce Study, between 2005 and 2015, the percentage of internal medicine residents entering rheumatology has remained…
Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
NEW YORK (Reuters Health)—Children of women with rheumatoid arthritis (RA) who are exposed to tumor necrosis factor-alpha inhibitors (TNFis) in the womb are not at markedly increased risk of serious infections, new findings suggest. “It’s reassuring for mothers who need to take these medications during pregnancy,” Evelyne Vinet, MD, of McGill University Health Center in…
Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles
NEW YORK (Reuters Health)—The interleukin 23 inhibitor guselkumab is associated with more improvement in psoriasis on the scalp, palms and/or soles compared with adalimumab, a new analysis suggests. Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center in Portland conducted a secondary analysis of data from the international VOYAGE 1 and VOYAGE 2 studies, double-blind,…
Existing CT Scans as Good as DXA for Assessing Hip Fracture Risk
NEW YORK (Reuters Health)—A “biomechanical” analysis of a previously taken pelvic or abdominal computed tomography (CT) scan is at least as accurate in assessing an individual’s hip fracture risk as a dual-energy X-ray absorptiometry (DXA) scan, according to new research. This accuracy of the hip bone mineral density (BMD) T-score as measured by the biomechanical…
Diclofenac May Boost MI Risk in Patients with Spondyloarthritis
NEW YORK (Reuters Health)—Risk of myocardial infarction (MI) is increased in patients with spondyloarthritis (SpA) who use the nonsteroidal anti-inflammatory drug (NSAID) diclofenac, but not in those who take naproxen, researchers say. Maureen Dubreuil, MD, MSc, of Boston University School of Medicine, and colleagues analyzed 20 years of medical records from the U.K.’s Health Improvement…
RA Patients May Not Receive Needed Osteoporosis Screening & Treatment
New research examined the frequency of osteoporosis screening and treatment for RA patients from 2003–2014, including four years following the release of the 2010 ACR guideline on glucocorticoid-induced osteoporosis prevention and treatment. The results: Approximately half of RA patients for whom treatment was indicated never received osteoporosis medication. Researchers also found that RA patients, despite their increased risk for developing osteoporosis, were not more likely to receive osteoporosis care than OA patients…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 98
- Next Page »